Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Scent dogs identify SARS-CoV-2-infections in respiratory samples from experimentally infected ferrets and hamsters-a pilot study.
Schulz C, Twele F, Meller S, Ten Hagen NA, Pilchová V, Wirz K, Clever S, Meyer Zu Natrup C, Volz A, von Köckritz-Blickwede M, Volk HA. Schulz C, et al. Among authors: volz a. Front Med (Lausanne). 2024 Dec 9;11:1476300. doi: 10.3389/fmed.2024.1476300. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39717173 Free PMC article.
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
Link EK, Tscherne A, Sutter G, Smith ER, Gurwith M, Chen RT, Volz A; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Link EK, et al. Among authors: volz a. Vaccine. 2025 Jan 1;43(Pt 1):126521. doi: 10.1016/j.vaccine.2024.126521. Epub 2024 Nov 28. Vaccine. 2025. PMID: 39612556 Free article. Review.
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.
Kumar S, Nan L, Kalodimou G, Jany S, Freudenstein A, Brandmüller C, Müller K, Girl P, Ehmann R, Guggemos W, Seilmaier M, Wendtner CM, Volz A, Sutter G, Fux R, Tscherne A. Kumar S, et al. Among authors: volz a. Int J Mol Sci. 2024 Oct 10;25(20):10898. doi: 10.3390/ijms252010898. Int J Mol Sci. 2024. PMID: 39456680 Free PMC article.
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423-7. doi: 10.1016/S1473-3099(24)00423-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389076
Associations of County-Level Social Determinants of Health with COVID-19 Related Hospitalization Among People with HIV: A Retrospective Analysis of the U.S. National COVID Cohort Collaborative (N3C).
Islam JY, Hurwitz E, Li D, Camacho-Rivera M, Sun J, Safo S, Ross JM, Wilkins K, Hassan S, Hill EL, Nosyk B, Varley C, Fadul N, Madlock-Brown C, Patel RC; N3C consortium. Islam JY, et al. AIDS Behav. 2024 Oct;28(Suppl 1):136-148. doi: 10.1007/s10461-024-04466-0. Epub 2024 Sep 18. AIDS Behav. 2024. PMID: 39292319 Free PMC article.
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
Clever S, Limpinsel L, Meyer Zu Natrup C, Schünemann LM, Beythien G, Rosiak M, Hülskötter K, Gregor KM, Tuchel T, Kalodimou G, Freudenstein A, Kumar S, Baumgärtner W, Sutter G, Tscherne A, Volz A. Clever S, et al. Among authors: volz a. Viruses. 2024 Mar 8;16(3):417. doi: 10.3390/v16030417. Viruses. 2024. PMID: 38543782 Free PMC article.
206 results